Dosage ; Initially 50-75mg nocte or in divided dose
(max. 150-200mg daily).
Elderly: ½ of the dose above.
Nocturnal enuresis: Children; 7-10 years 10-20mg nocte,
11-16 years: 25-50mg nocte for max. period of 3 months
(including gradual withdrawal).
Combinations; Amitriptyline / Chlordiazepoxide- see below
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Amitrip | Laboratory & Allied Ltd. | Laboratory & Allied Ltd | 25mg | 100 | Tablet | per tablet | KES 70.00 |
| Amitrip | Laboratory & Allied Ltd. | Laboratory & Allied Ltd | 25mg | 1000 | Tablet | per tablet | KES 450.00 |
| Amitriptyline | Biodeal Laboratories Ltd. | Biodeal Laboratories Ltd. | 25mg | 1000 | Tablet | per tablet | KES 600.00 |
| Amitriptyline | Biodeal Laboratories Ltd. | Biodeal Laboratories Ltd. | 25mg | 100 | Tablet | per tablet | KES 100.00 |
| Amitriptyline | Biodeal Laboratories Ltd. | Biodeal Laboratories Ltd. | 25mg | 100 | Tablet | per tablet | KES 100.00 |
| Amitriptyline | Cosmos Limited. | Cosmos Limited | 25mg | 100 | Tablet | per tablet | KES 130.00 |
| Amitriptyline | Universal Pharmaceuticals Ltd. | Universal Corporation Ltd | 25mg | 100 | Tablet | per tablet | KES 113.00 |
| Tryptil | Prism Life Sciences | Galaxy Pharmaceuticals Ltd | 25mg | 100 | Tablet | per tablet | KES 120.00 |
| Laroxyl | 25mg | 12s | Tablet | Per Tablet | KES 50 .00 |
Amitriptyline More info |
|||||
|---|---|---|---|---|---|
| Mode Of Action | The mechanism of action of amitriptylinne is not fully known but may be due to its increasing the synaptic concentration of norepinephrine and/or serotonin in the central nervous system (CNS). These neurotransmitters are thought to be increased through inhibition of their reuptake by the presynaptic neuronal membrane. |
||||
| Drug Indication | Depressive illness; useful in depression associated with anxiety and sleep disturbances; chronic neurogenic pain; and bulimia nervosa; temporary treatment of nocturnal enuresis in children 6 years of age or older. | ||||
| Precautions | Blood monitoring; history of epilepsy; pregnancy and lactation; history of mania; close angle glaucoma; concurrent electroconvulsive therapy; anaesthesia; elderly; hepatic impairment; psychosis; withdraw gradually. | ||||
| Contra-Indications | Severe hepatic disorders; acute recovery phase following myocardial infarction; hypersensitivity to tricyclic drugs; MAOIs. | ||||
| Side Effects | Antimuscarinic actions namely: drowsiness; urinary retention; dry mouth; constipation; blurred vision; sweating; hypotensive effect, which may lead to dizziness and syncope. Arrhythmias and heart block; convulsions; haematological and hepatic reactions | ||||
| Dosage | Initially 50-75mg nocte or in divided dose (max. 150-200mg daily). Elderly: ½ of the dose above. Nocturnal enuresis: children; 7-10 years 10-20mg nocte, 11-16 years: 25-50mg nocte for max. period of 3 months (including gradual withdrawal). | ||||
| Special Information | It has high anticholinergic and sedative effects and moderate to high orthostatic hypotensive effects. | ||||
| Pregnancy Category | Category C | ||||
| Pregnancy Category Description | Drugs which, owing to their pharmacological effects, or may be suspected of causing detrimental effects on human foetus or neonates without causing malfunctions. These effects may be reversible | ||||
| Drug Category | DRUGS ACTING ON CNS | ||||
| Drug Sub-Category | Antidepressants, anxiolytics
Use; Relief of symptoms of depression Use - Unlabeled/Investigational Analgesic for certain chronic and neuropathic pain (including diabetic neuropathy); prophylaxis against migraine headaches; treatment of depressive disorders in children; post-traumatic stress disorder (PTSD) Dosing: Adult Depression: Oral: 50-150 mg/day single dose at bedtime or in divided doses; dose may be gradually increased up to 300 mg/day. Chronic pain management (unlabeled use): Oral: Initial: 25 mg at bedtime; may increase as tolerated to 100 mg/day. Diabetic neuropathy (unlabeled use): Oral: 25-100 mg/day (Bril, 2011) Migraine prophylaxis (unlabeled use): Oral: Initial: 10-25 mg at bedtime; usual dose: 150 mg; reported dosing ranges: 10-400 mg/day Post-traumatic stress disorder (PTSD) (unlabeled use): Oral: 75-200 mg/day Dosing: Pediatric (For additional information see "Amitriptyline: Pediatric drug information") Chronic pain management (unlabeled use): Oral: Initial: 0.1 mg/kg at bedtime, may advance as tolerated over 2-3 weeks to 0.5-2 mg/kg at bedtime Depressive disorders: Children (unlabeled use): Oral: Initial doses of 1 mg/kg/day given in 3 divided doses with increases to 1.5 mg/kg/day have been reported in a small number of children (n=9) 9-12 years of age; clinically, doses up to 3 mg/kg/day (5 mg/kg/day if monitored closely) have been proposed Adolescents: Initial: 25-50 mg/day; may administer in divided doses; increase gradually to 100 mg/day in divided doses. Migraine prophylaxis (unlabeled use): Oral: Initial: 0.25 mg/kg/day, given at bedtime; increase dose by 0.25 mg/kg/day to maximum 1 mg/kg/day. Reported dosing ranges: 0.1-2 mg/kg/day; maximum suggested dose: 10 mg. Dosing: Geriatric Depression: Oral: Initial: 10-25 mg at bedtime; dose should be increased in 10-25 mg increments every week if tolerated; dose range: 25-150 mg/day. See Renal/Hepatic Impairment. Dosing: Renal Impairment; Nondialyzable Amitriptyline / Chlordiazepoxide
|
||||